Instrument
🇰🇷 Hanmi Pharm
KR (Korea) · 128940 · 한미약품
Today's Score
0.21
weak (yesterday 0.20)30-day score trend
📊 Quant score trend
Last 30d quant score (PER/PBR/ROE/debt/margin/growth sector percentile)
PER 32.4 / PBR 4.26 / ROE 14.5% / 부채비율 50% / 이익률 16.7% / 매출성장 +3.5% / 이익성장 +33.3%
Not a buy or sell signal. Informational only.
📊 Latest earnings — 2026-03-31
Revenue
392.9B
YoY +8.8%
QoQ -74.6%
Operating income
53.6B
YoY -11.2%
Net income
—
YoY —
Informational — not a buy signal. Source: DART
🕸️ Metrics radar
Each axis is 0-100. Higher means stronger on that dimension.
Informational — 5 axes are 0-100 percentile, compared to sector average
Market regime — 🇰🇷 KR (Korea)
SIDE "이번 주 -7.0%. 큰 움직임 없이 어깨를 한 번 으쓱한 정도였어요."
📈 7-day price
📋 Recent filings (DART)
- 07-02 임원ㆍ주요주주특정증권등소유상황보고서
- 06-11 기업설명회(IR)개최(안내공시)
- 06-10 지속가능경영보고서등관련사항(자율공시)
Source: DART (Korean electronic disclosure). Reference only.
📰 Recent news
-
한미약품 차남 임종훈, 지주사 지분 제3자에 일부 매각... "어머니·누나...
07-02 · Naver
-
임종훈 한미정밀화학 대표, 한미사이언스 지분 2.5% 매각…경영권 분쟁...
07-02 · Naver
-
한미 차남 임종훈, 신동국 대신 엄마 택했다…나우IB에 지분 매각 [시그...
07-02 · Naver
Source: Naver. Not Tradory's opinion.
🔎 Compare info
Click a button to see database-backed metrics. Informational only, not buy or sell signals.
ⓘ This compares public financial and market data. Not a buy or sell opinion.
See more after signing up
- • 5-year full chart (D/W/M/Y + RSI/MACD)
- • DCA simulation + market index comparison
- • Watchlist + email alerts
ⓘ Informational summary, not a buy or sell signal. Past data does not guarantee future returns.